PubMed Health⌕ Search

Biomedical subjects

M Baranowski

Publications and source records attributed to M Baranowski.

15 recordsLinked to original sources
PubMed2004

Metabolic profile of pigs fed feed containing zearalenone destructor.

Zearalenone (ZEA) is a member of macrocyclic lactons family. It is a toxin--phytosteride produced by fungi of Fusarium ssp. genus. Zearalenone contaminates food and animal feeding stuffs and its destruction is difficult. It requires application of particular compounds that would bind zearalenone in the feed or feeding stuff or in the gastrointestinal tract and decrease its bio-accessibility. It should also fulfil all the safety requirements regarding the plant supplements and animals that are fed with this feed. The aim of the study was to estimate if the feed supplemented with different doses of zearalenone and zearalenone destructor causes changes of the metabolic profile in gilts. The results obtained show that applied destructor did not cause negative haematological and biochemical changes in the blood of the gilts examined. It can be suggested that it is a safe feed supplement pigs in prevention of zearalenone micotoxicosis.

Animal Feed↗
PubMed2004

The occurrence of zearalenone and its derivatives in standard and therapeutic feeds for companion animals.

Weather anomalies are the cause of the more and more frequent occurrence of the rezorcycyklic acid derivatives--zearalenone--in the fodders of the animal origin. This mycotoxine induces in the organism of gilts an oestrus-like condition. According to the latest reports the zearalenone derivatives were found in the human food-stuffs in the retail market. It was considered important to assay the concentration of zearalenone and its derivatives in the standard and therapeutic feeds for dogs. Zearalenone and its derivatives were found in 48 commercial formulations for a total number of 57 brands analysed.

Animal Feed↗
PubMed1999

The estimation of endogenous tumor necrosis factor alpha and cortisol levels in serum in advanced neoplasm.

The immune reaction mediators--cytokines may play an important role in central nervous system function and influence the neuroendocrine system. The aim of the study was to assess the hypothesis of a possible correlation between endogenous TNF-alpha and glucocorticoids secretion in advanced neoplasm. Thirty patients (17 males and 13 females) with advanced neoplasm were enrolled in the study. The levels of TNF-alpha were measured with ELISA type test and cortisol levels were estimated by RIA method. The blood samples were collected 6 times during 24-hours for TNF and 6 times a day for cortisol. Twenty healthy volunteers were studied in parallel. Both TNF-alpha and cortisol levels revealed the presence of circadian rhythm in examined patients. The levels of TNF-alpha were very high and achieved the peak value about midnight (acrophase-01.40). Cortisol peak was found typically at 08.08. The fluctuations of examined molecules showed regular patterns. TNF-alpha levels markedly decreased together with the increase of cortisol and rose when cortisol concentration in serum was low. Although the correlation was not confirmed by Spearman correlation rank the shapes displayed by both curves may suggest the presence of neuroendocrine feed-back loop between corticosteroids and TNF-alpha in advanced cancer.

Aged↗
PubMed1998

Circadian rhythmometry of serum endogenous tumor necrosis factor-alpha in patients with colorectal cancer metastases.

The objective of this study was to test the hypothesis of a diurnal fluctuation of circulating levels of endogenous tumor necrosis factor-alpha (TNF-alpha) in patients with colorectal cancer metastases. Serum levels of TNF-alpha were measured 6 times a day in 27 colorectal cancer patients as well as in healthy controls. The levels of TNF-alpha in serum from healthy controls were close to the detection limit of the method or were not detectable at all. Serum TNF-alpha levels in advanced cancer patients were substantially increased. Peak values appeared at 2 a.m. In contrast, the levels were low in the afternoon (2 p.m). The presence of a circadian rhythm was found with the acrophase at 0 hour 40 min.

Adult↗
PubMed1997

[Monitoring of changes in levels of endogenous TNF alpha in patients with uncontrolled insulin dependent diabetes mellitus].

In 27 patients with uncontrolled type 1 diabetes the changes of the endogenous TNF alpha serum concentration in correlation with blood glucose level were investigated. In the first 24 hours period, the concentration of glucose was analysed in the following way: immediately after the admission, next every hour for three hours and then after 6, 9, 12, 18 and 24 hours. In the followed days the blood glucose was determined five times a day. The serum concentration of endogenous TNF alpha was monitored immediately after the admission, after first hour of treatment and next after 6, 24, 72 hours. The control group consisted of 23 healthy persons. Glycaemia level and TNF alpha concentration were analyzed with Student-1 test for combined variables and the correlation Spearmann test. The level of TNF alpha markedly decreases together with the decrease of blood glucose level in each patient. The level of TNF correlates with the level of glycaemia (linear correlation). The results presented above unequivocally show that there is a correlation between endogenous TNF alpha and glucose level in serum of the patients with type 1 diabetes (at the decompensation stage of the disease).

Adult↗
PubMed1996

Tumor necrosis factor in advanced gastrointestinal neoplasms. A clinical trial with a focus on haematological effects.

This paper presents the results of the clinical trial with the use of hr TNF-alpha (human recombinant tumor necrosis factor-alpha) in 16 advanced gastrointestinal cancer patients. Hr TNF-alpha was administered intravenously in a short, 30-min infusion. According to authors' previous experiences with daily dose escalation (modified Fibonacci scheme), a daily dose of 150 microg/m2 was established as safe, and was well tolerated by the patients. The treatment consisted of 5-day cycles, repeated six times, every 14 days. Special attention was paid regarding the possible side-effect and safety of hr TNF-alpha administration in men, as many acute and chronic haematological toxicities have been reported. After careful analysis of TNF-alpha side-effects, we did not find any acute haematological complications (e.g. thrombosis, DIC, embolism) in any of the patients. Haemoglobin values and erythrocyte and leucocyte counts gradually decreased during each cycle, with the tendency for spontaneous renewal after the treatment had been completed. No cases of thrombocytopenia and severe neuropenia were observed.

Adult↗
PubMed1996

[Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms].

The group of 17 patients with advanced neoplastic disease has been treated with combined therapy with herec TNF alpha in association with IFN alpha and 5-Fu, the cardiotoxic effect of herec TNF alpha administration has been observed. The 30 minutes intravenous infusion of herec TNF alpha caused statistically significant increase of heart rate (in comparison to the previous value). There was also observed the decreasing of blood pressure value (about approximately 20-30 mmHg), spontaneously disappeared after the infusion ending. Rarely, the heart rhythm disturbances i.e.: ventricle extrasystoles in II, III, IV in Lown score have been observed. In 2 cases there was additional pharmacological treatment. In the rest of the patients the early cardiotoxic effects have not been associated with haemodynamic disturbances.

Adult↗
PubMed1996

[A case of recurrent untreated non-hodgkin's lymphoma localized in the nasopharynx and maxillary sinuses after a 10-year remission].

We present the case of non-Hodgkin lymphoma (lymphoma malignum lymphocyticum) localised in nasal cavity and paranasal sinus (maxillary sinus). The patient suffered from weakness, fever and rhinorrhoea. We applied the chemotherapy (grade IV degrees) in COP, achieving partial remission. We also place emphasis on 10-year period of idiopathic neoplasm remission since the establishment of diagnosis.

Adult↗
PubMed1995

[Effect of intravenous treatment with tumor necrosis factor alpha in patients with advanced cancer--phase I clinical trials].

Tumor necrosis factor (TNF) is the protein produced by the activated macrophages with the ability to produce haemorrhagic necrosis of tumor, and in some cases complete tumor remission in vivo, as well as cytotoxicity of neoplastic cells in vitro. These properties made us undertake clinical studies on THF. We performed a Phase I assessment of recombinant human THF alpha in 16 patients with advanced solid neoplasms. Therapy consisted of a 30 minute intravenous (IV) infusion on day i thraugh 5, every 2 weeks. Daily doses ranged from 25 micrograms/m2 to 200 micrograms/m2. Side effects hypotension tachycardia nausea or vomiting, headache. No major changes in liver or renal function were seen.

Adult↗
PubMed1990

[Various patterns of behavior in patients with ulcerative colitis and duodenal ulcer].

The subject of the study was in a trial of evaluation of selected behavioral patterns in patients with ulcerative colitis and acidpeptic disease of duodenum. As an evaluation method was employed the psychometric method consisting of the use of Nonconventional Adjectives Test the usefulness of which was confirmed in previous publications. The group of patients studied consisted of 65 persons with duodenal acid-peptic disease, 41 persons with ulcerative colitis and 72 healthy subject as a control group. The results obtained presented in a graphical manner reflected the psychological differences between above groups. Patients with ulcerative colitis were characterized by an increased fineness, sensibility or emotionality whereas those with duodenal acid-peptis disease selected adjectives indicating the lowered ability of self-control and of control on other people when compared with health subjects.

Adult↗
PubMedDate not supplied

Fluctuation of endogenous TNF alpha concentration in plasma in advanced cancer patients.

OBJECTIVES: To test the hypothesis of a fluctuation of circulating levels of endogenous Tumor Necrosis Factor alpha (TNF alpha) in patients with advanced gastrointestinal cancer. METHODS: Serum levels of TNF alpha were measured at 8 a.m., 3 p.m., midnight and 3 a.m. in 21 patients with advanced cancer. RESULTS: Serum TNF alpha levels were substantially increased in patients with advanced cancer as compared to healthy subjects. Peak value appeared at 3 a.m., and gradually declined to very low levels in the afternoon (3 p.m.). Using cosinor least square methods we could not find the circadian rhythm of TNF alpha.

Circadian Rhythm↗
PubMedDate not supplied

Is there a correlation between tumor necrosis factor alpha and soluble p-55 receptor plasma levels in advanced gastrointestinal cancer patients?

UNLABELLED: Studies have shown an increased spontaneous TNF alpha production, and the 24--rhythmicity of TNF blood concentration in patients with advanced cancer. The present study investigates whether diurnal rhythmicity of endogenous TNF alpha is associated with the induction of circulating sTNF Rp55 in advanced gastrointestinal neoplasm. The levels of endogenous TNF alpha and sTNF Rp55 in serum were measured at 8 a.m., 2 p.m., 6 p.m., 10 p.m., 2 a.m., and again at 8 a.m. RESULTS: There is circadian rhythm in the secretion of endogenous TNF alpha in patients with advanced gastrointestinal cancer, however no diurnal rhythm of sTNF Rp55 was observed. Since it has been suggested that human tumors susceptible to TNF alpha may escape destruction by secreting or inducing the secretion of sTNF Rp55 to block the effects of TNF alpha, the possibility that the observed fluctuations could also reflect the complexation of a proportion of the receptor molecules with their ligand should be considered.

Adult↗
PubMedDate not supplied

[Treatment of advanced pancreatic cancer with interferon alpha, tumor necrosis factor and 5-fluorouracil (preliminary report].

This paper presents the first outcomes of a combined therapy of advanced cancer of pancreas with Interferon alpha, Tumor Necrosis and 5-Fluorouracil. Every subject underwent surgical treatment, but only in two cases partial resection was done. In the other subject only palliative operations were performed because of advances stages of neoplastic process. All patients were followed up during the time ranged between from 2.5-13.5 months. Complete remission was observed in one patient (survival time--9 months). In three subjects partial remission was reported, whereas in the left part of our cohort the general condition was steady. This research would be continued.

Adenocarcinoma↗